NCT05245682View on ClinicalTrials.gov

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

January 15, 2024

Study Completion Date

October 21, 2025

Conditions
Head and Neck Carcinoma of Unknown PrimaryLocally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaLocally Advanced Nasopharyngeal Squamous Cell CarcinomaLocally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Tolinapant

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER